HUP0400991A3 - Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i, process for their preparation and pharmaceutical compositions containing them - Google Patents

Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
HUP0400991A3
HUP0400991A3 HU0400991A HUP0400991A HUP0400991A3 HU P0400991 A3 HUP0400991 A3 HU P0400991A3 HU 0400991 A HU0400991 A HU 0400991A HU P0400991 A HUP0400991 A HU P0400991A HU P0400991 A3 HUP0400991 A3 HU P0400991A3
Authority
HU
Hungary
Prior art keywords
diazepin
benzo
dihydro
derivatives
preparation
Prior art date
Application number
HU0400991A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HUP0400991A2 publication Critical patent/HUP0400991A2/hu
Publication of HUP0400991A3 publication Critical patent/HUP0400991A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HU0400991A 2001-04-12 2002-04-02 Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i, process for their preparation and pharmaceutical compositions containing them HUP0400991A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109126 2001-04-12
PCT/EP2002/003643 WO2002083665A1 (en) 2001-04-12 2002-04-02 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I

Publications (2)

Publication Number Publication Date
HUP0400991A2 HUP0400991A2 (hu) 2004-08-30
HUP0400991A3 true HUP0400991A3 (en) 2009-06-29

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400991A HUP0400991A3 (en) 2001-04-12 2002-04-02 Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i, process for their preparation and pharmaceutical compositions containing them

Country Status (37)

Country Link
US (1) US6548495B2 (enExample)
EP (1) EP1379522B1 (enExample)
JP (1) JP4043953B2 (enExample)
KR (1) KR100566178B1 (enExample)
CN (1) CN1268626C (enExample)
AR (1) AR035456A1 (enExample)
AT (1) ATE287883T1 (enExample)
AU (1) AU2002310912B2 (enExample)
BG (1) BG108253A (enExample)
BR (1) BR0208887A (enExample)
CA (1) CA2441771C (enExample)
CZ (1) CZ20033002A3 (enExample)
DE (1) DE60202761T2 (enExample)
DK (1) DK1379522T3 (enExample)
EC (1) ECSP034796A (enExample)
ES (1) ES2235044T3 (enExample)
GT (1) GT200200072A (enExample)
HR (1) HRP20030791B1 (enExample)
HU (1) HUP0400991A3 (enExample)
IL (2) IL158021A0 (enExample)
JO (1) JO2273B1 (enExample)
MA (1) MA27011A1 (enExample)
MX (1) MXPA03009317A (enExample)
MY (1) MY130369A (enExample)
NO (1) NO325300B1 (enExample)
NZ (1) NZ528345A (enExample)
PA (1) PA8543201A1 (enExample)
PE (1) PE20021072A1 (enExample)
PL (1) PL367086A1 (enExample)
PT (1) PT1379522E (enExample)
RU (1) RU2270197C2 (enExample)
SI (1) SI1379522T1 (enExample)
SK (1) SK13692003A3 (enExample)
UY (1) UY27259A1 (enExample)
WO (1) WO2002083665A1 (enExample)
YU (1) YU79103A (enExample)
ZA (1) ZA200307242B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2215738T3 (es) * 1999-10-15 2004-10-16 F. Hoffmann-La Roche Ag Derivados de benzodiazepina como receptor de glutamato metabotropico.
SI1651234T1 (sl) * 2003-07-25 2008-02-29 Hoffmann La Roche Kombinacija antagonista mglur2 in inhibitorja ache za zdravljenje akutnih in/ali kronicnih nevroloskih motenj
DE602005008095D1 (de) 2004-11-05 2008-08-21 Hoffmann La Roche Verfahren zur herstellung von isonikotinsäurederivaten
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CN101657432B (zh) 2007-04-19 2013-04-10 弗·哈夫曼-拉罗切有限公司 二氢-苯并[b][1,4]二氮杂*-2-酮磺酰胺衍生物
MX2010002536A (es) 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetrahidro-2h, 1'h-[1,4]bipiridinil-2'-onas 1',3'-disubstituidas.
EP2205565B1 (en) * 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 1,3-이치환된 4-(아릴-x-페닐)-1h-피리딘-2-온
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011002042A (es) 2008-09-02 2011-06-20 Ortho Mcneil Janssen Pharm Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico.
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
EA020672B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалс, Инк. Производные 1,2,4-триазоло[4,3-a]пиридина и их применение для лечения или предупреждения неврологических и психиатрических расстройств
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
CN104736140A (zh) 2012-10-23 2015-06-24 霍夫曼-拉罗奇有限公司 用于治疗自闭症的mGlu2/3拮抗剂
LT2963043T (lt) * 2013-02-28 2018-10-10 Eisai R&D Management Co., Ltd. Tetrahidroimidazo[1,5-d][1,4]oksazepino darinys
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
UA121965C2 (uk) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
KR102502485B1 (ko) 2014-01-21 2023-02-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
JP2017513844A (ja) 2014-04-23 2017-06-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 知的障害の処置のためのmGlu2/3アンタゴニスト
AU2015274781C1 (en) * 2014-06-10 2019-08-08 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU953819A1 (ru) * 1980-08-25 1991-09-23 Физико-химический институт АН УССР 1-(Гидразинокарбонил)алкил-1,2-дигидро-3Н-1,4-бенздиазепин-2-оны, обладающие транквилизирующими и противосудорожными свойствами
WO2001010846A2 (en) * 1999-08-05 2001-02-15 Igt Pharma Inc. 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
ES2215738T3 (es) * 1999-10-15 2004-10-16 F. Hoffmann-La Roche Ag Derivados de benzodiazepina como receptor de glutamato metabotropico.
HRP20020259A2 (en) * 1999-10-15 2004-04-30 Hoffmann La Roche Benzodiazepine derivatives

Also Published As

Publication number Publication date
AR035456A1 (es) 2004-05-26
CZ20033002A3 (cs) 2004-03-17
MA27011A1 (fr) 2004-12-20
US20020198197A1 (en) 2002-12-26
DE60202761T2 (de) 2006-01-12
DE60202761D1 (de) 2005-03-03
MY130369A (en) 2007-06-29
JP4043953B2 (ja) 2008-02-06
RU2003130648A (ru) 2005-04-10
PE20021072A1 (es) 2002-12-07
CA2441771C (en) 2008-12-30
CN1268626C (zh) 2006-08-09
EP1379522B1 (en) 2005-01-26
CN1522252A (zh) 2004-08-18
YU79103A (sh) 2006-05-25
NO20034496D0 (no) 2003-10-08
SI1379522T1 (en) 2005-04-30
PL367086A1 (en) 2005-02-21
HRP20030791A2 (en) 2005-06-30
BG108253A (bg) 2005-03-31
US6548495B2 (en) 2003-04-15
IL158021A (en) 2010-04-15
GT200200072A (es) 2003-06-19
IL158021A0 (en) 2004-03-28
CA2441771A1 (en) 2002-10-24
SK13692003A3 (sk) 2004-05-04
ECSP034796A (es) 2003-12-01
ES2235044T3 (es) 2005-07-01
NO325300B1 (no) 2008-03-25
JO2273B1 (en) 2005-04-07
JP2004525965A (ja) 2004-08-26
HK1068339A1 (en) 2005-04-29
KR100566178B1 (ko) 2006-03-29
KR20030088502A (ko) 2003-11-19
BR0208887A (pt) 2004-06-29
ATE287883T1 (de) 2005-02-15
WO2002083665A1 (en) 2002-10-24
PA8543201A1 (es) 2002-10-31
RU2270197C2 (ru) 2006-02-20
PT1379522E (pt) 2005-05-31
NO20034496L (no) 2003-10-08
MXPA03009317A (es) 2004-02-12
DK1379522T3 (da) 2005-05-30
UY27259A1 (es) 2002-10-31
EP1379522A1 (en) 2004-01-14
HRP20030791B1 (en) 2006-06-30
ZA200307242B (en) 2004-12-16
HUP0400991A2 (hu) 2004-08-30
NZ528345A (en) 2005-04-29
AU2002310912B2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
HUP0400851A3 (en) Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists ii, process for their preparation and pharmaceutical compositions containing them
HUP0400991A3 (en) Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i, process for their preparation and pharmaceutical compositions containing them
HUP0402026A3 (en) 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0203294A3 (en) Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203902A3 (en) Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
HUP0203142A3 (en) Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0203548A3 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0105432A3 (en) New biphenyl and biphenyl-analogous compounds as integrin antagonists, process for their preparation and pharmaceutical compositions containing them and their use
HUP0204245A3 (en) Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0300618A3 (en) Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0203052A3 (en) Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203836A3 (en) 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use
HUP0203316A3 (en) Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them
SI1192122T1 (en) Benzene derivatives, preparation method and pharmaceutical compositions containing same
HUP0202731A3 (en) O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0201516A3 (en) 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0303156A3 (en) Substituted 2-phenylaminoimidazoline derivatives as ip antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0201753A3 (en) Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203140A3 (en) Bicyclic imidazo-5-yl-amine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0201402A3 (en) Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
HUP0203184A3 (en) Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0200281A2 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0203526A3 (en) Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0100489A3 (en) New piperidine-4-sulphonamide compounds, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal